GlassScriptPhysician profile
William F Lapenna
NPI 1154302347
$5,902.17
in general payments reported to CMS, 2019-2025
27 companies · $679 in 2025
The $679 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $457 · 2021: $539 · 2022: $985 · 2023: $892 · 2024: $1,699 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,269.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,010.43 | 2019-2024 | Amplatzer Amulet, Dragonfly Opstar, Amplatzer Talisman |
| Novartis Pharmaceuticals Corporation | $971.49 | 2021-2025 | |
| Boston Scientific Corporation | $657.06 | 2019-2025 | Avvigo Guidance System, Rotapro, Emblem Mri S-Icd |
| Shockwave Medical, INC | $384.72 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $370.88 | 2022-2025 | Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.30 | 2019-2025 | Lifevest |
| Abiomed | $312.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $302.63 | 2021-2025 | Camzyos, Eliquis |
| Cordis US Corp. | $290.58 | 2022-2025 | Mynxgrip, Radial 360 |
| Amgen INC. | $207.39 | 2020-2023 | Repatha |
| Inari Medical, INC. | $179.78 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Penumbra, INC. | $141.21 | 2024 | Indigo System |
| Stryker Corporation | $128.31 | 2025 | Flowtriever |
| Cardinal Health 200 LLC | $118.33 | 2019-2021 | |
| Chiesi USA, INC. | $110.09 | 2022-2024 | Kengreal, Cleviprex |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $94.07 | 2024 | Assure Wcd |
| Zoll Circulation INC | $37.57 | 2023-2024 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Bayer Healthcare Pharmaceuticals INC. | $35.45 | 2025 | |
| Angiodynamics, INC. | $34.66 | 2024 | Alphavac |
| Imperative Care, INC | $30.50 | 2024 | Symphony Catheter |
| Astrazeneca Pharmaceuticals LP | $26.39 | 2019 | |
| Pfizer INC. | $24.61 | 2025 | |
| Acist Medical Systems, INC. | $22.45 | 2024 | |
| W. L. Gore & Associates, INC. | $21.19 | 2024 | Gore Excluder Aaa Endoprosthesis |
| Heartflow, INC. | $17.13 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.49 | 2023 | Inpefa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$399,998.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lapenna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.